

REMARKS

Claims 21-32 are currently pending in the application. By this amendment, claims 27-28, 30 and 32 have been amended, claims 1-20 having been cancelled by Examiner's amendment. The foregoing separate sheets marked as "Listing of Claims" shows all the claims in the application, with an indication of the current status of each.

Applicant thanks Examiner for the indication that claims 21-32 of the application are allowable. However, Applicant notes that, while Examiner states that new claims 21-32 are identical to claim 1-7, 10, 12, 13, 15, and 17 presented by Applicants (in the response filed July 7, 2006), this is not the case. Applicant has reviewed the claims of that response and notes the following:

- 1) Previous claims 10 and 12 (now claims 28 and 30, respectively) both included the statement "with the proviso that if R is CH₃ then X must be CH₂ or a saturated C₂ carbon chain". Applicant has hereby amended claims 28 and 30 to include this statement, thereby restoring the language of claims 10 and 12.
- 2) New claim 32 (previously claim 17) contains two incorrect references to "agonist". The agent used and first recited in claim 32 is a silent antagonist. Previous claim 17 correctly recited "said silent antagonist". Present claim 32 has hereby been amended to recite "said silent antagonist" in the two places in the claim where this is appropriate, thereby restoring the language of claim 17.
- 3) Claims 30 and 32 (previously 13 and 17) have hereby been amended to include the word "a" before the phrase "CBI cannabinoid receptor". This restores the language of these two claims to that of the claims on which they are based (13 and 17) and is more consistent with correct English.

Other matters Claim 27 is hereby amended to recite that the step of the method is "administering to said patient a compound of formula...wherein said compound is administered in a quantity sufficient to ameliorate symptoms of said condition or disorder". Applicant submits that this amendment adds no new matter, being entirely formal in nature, and serving to clarify the language of the claim. Applicant respectfully requests allowance of claim 27 as amended.

Conclusion

Entry of the amendment prior to issuance of the patent is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Ruth E. Tyler-Cross", with a stylized flourish extending to the right.

Ruth E. Tyler-Cross
Reg. No. 45,922

Whitham, Curtis, Christofferson & Cook, P.C.
11491 Sunset Hills Road, Suite 340
Reston, VA 20190
703-787-9400(tel)
703-787-7557 (fax)